Last reviewed · How we verify
COV795
COV795 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
COV795 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Autoimmune or inflammatory conditions (specific indication under investigation in phase 3).
At a glance
| Generic name | COV795 |
|---|---|
| Also known as | MNK795 |
| Sponsor | Mallinckrodt |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce excessive inflammatory responses in conditions characterized by dysregulated immune activation.
Approved indications
- Autoimmune or inflammatory conditions (specific indication under investigation in phase 3)
Common side effects
- Nausea
- Headache
- Diarrhea
- Vomiting
Key clinical trials
- Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain (PHASE3)
- Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COV795 CI brief — competitive landscape report
- COV795 updates RSS · CI watch RSS
- Mallinckrodt portfolio CI